Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors

Advances in understanding the myeloma biology have shown that disease progression is not only the consequence of intrinsic tumor changes but also of interactions between the tumor and the microenvironment in which the cancer grows. Immune system is an important component of the tumor microenvironment in myeloma, and acting on immune system is an appealing new treatment strategy. There are 2 ways to act towards immune cells and boost anti-tumor immunity: 1) to increase antitumor activity (acting on T and NK cytotoxic cells); and 2) to reduce immunosuppression (acting on myeloid-derived stem-cells and T regulatory cells).

Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Francesca Gay, Mattia D ’Agostino, Luisa Giaccone, Mariella Genuardi, Moreno Festuccia, Mario Boccadoro, Benedetto Bruno Tags: Review Article Source Type: research